2017•PubMedRequires access
[Clinical value of the early use of ulinastatin in patients with moderately severe or severe acute pancreatitis].
J Wang, Jong‐Youl Jin, Jing Huang, D R Li, Ying-Xia Hao, Jian Kong, Zachary Chu, J H Fu, Feng Huang
Open publisher page 8 citations
Abstract
The early use of ulinastatin in the patients with MSAP/SAP can down-regulated the levels of TNF-α, IL-6 and IL-8, reduce the inflammatory response, decrease intra-abdominal pressure and shorten abdominal pain time. It was beneficial and worthy of wider popularization.